Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study

Daijo Inaguma1 · Enyu Imai2 · Ayano Takeuchi3 · Yasuo Ohashi4 · Tsuyoshi Watanabe5 · Kosaku Nitta6 · Tadao Akizawa7 · Seiichi Matsuo8 · Hirofumi Makino9 · Akira Hishida10 · For The Chronic Kidney Disease Japan Cohort Study Group

Received: 10 May 2016 / Accepted: 6 July 2016 / Published online: 13 July 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Background Chronic kidney disease (CKD) eventually progresses to end-stage renal disease (ESRD). However, risk factors associated with CKD progression have not been well characterized in Japanese patients with CKD who are less affected with coronary disease than Westerners.

Methods A large-scale, multicenter, prospective, cohort study was conducted in patients with CKD and under nephrology care, who met the eligibility criteria [Japanese; age 20–75 years; and estimated glomerular filtration rate (eGFR): 10–59 mL/min/1.73 m²]. The primary endpoint was a composite of time to a 50 % decline in eGFR from baseline or time to the initiation of renal replacement therapy (RRT). The secondary endpoints were the rate of decline in eGFR from baseline, time to a 50 % decline in eGFR from baseline, time to the initiation of RRT, and time to doubling of serum creatinine (Cre) concentration.

Results 2966 patients (female, 38.9 %; age, 60.3 ± 11.6 years) were enrolled. The incidence of the primary endpoint increased significantly (P < 0.0001) in concert with CKD stage at baseline. The multivariate Cox proportional hazards models revealed that elevated systolic blood pressure (SBP) [hazard ratio (HR) 1.203, 95 % confidence interval (CI) 1.099–1.318] and increased albumin-to-creatinine ratio (UACR ≥ 1000 mg/g Cre; HR: 4.523; 95 % CI 3.098–6.604) at baseline were significantly associated (P < 0.0001, respectively) with the primary endpoint.

Conclusions Elevated SBP and increased UACR were risk factors that were significantly associated with CKD progression to ESRD in Japanese patients under nephrology care.

UMIN clinical trial registry number: UMIN000020038.

Keywords Chronic kidney disease · Estimated glomerular filtration rate · Urine albumin-to-creatinine ratio

Introduction

Chronic kidney disease (CKD) eventually progresses to end-stage renal disease (ESRD: maintenance dialysis or kidney transplantation). The proportion of patients with CKD is higher in Japan than in foreign countries. The estimated number of CKD patients is approximately 13.3 million, representing about 13 % of the Japanese adult population [1]. Risk factors—which are associated with the declined renal function of patients with CKD—include...
hypertension, diabetes mellitus (DM), cardiovascular disease (CVD), proteinuria, anemia, and administration of angiotensin receptor blockers (ARBs) [2].

The Chronic Kidney Disease Japan Cohort (CKD-JAC) study was planned in consideration of the Chronic Renal Insufficiency Cohort (CRIC) study in the US [3, 4]. The CKD-JAC Study is uniquely featured by the facts that its cohort consisted of a single race and that all enrolled patients were treated by nephrologists. Racial differences in CKD progression to ESRD have been noted between blacks and whites [5]. The rate of decline in estimated glomerular filtration rate (eGFR) is faster in Asians than in Caucasians [6]; however, the Kidney Disease: improving Global Outcomes CKD Work Group 2012 clinical practice guideline [7] does not contain the description. Nevertheless, any well-designed prospective clinical study has not been conducted to examine the renal prognosis of Japanese patients with CKD who were under nephrology care. The objective of the present study was to identify risk factors for CKD progression to ESRD in these patients.

Subjects and methods

Study organization

The CKD-JAC study established the Steering Committee, the Event Assessment Panel, as well as the Data Coordinating Center and determined 17 participating medical institutions, the central laboratories, and scientific advisors. The study protocol was approved by the institutional review boards at the institutions, and the study was conducted in accordance with the Declaration of Helsinki of 1975, as revised in 2005, and in compliance with the current regulations.

Study design

The CKD-JAC study was designed as a large-scale, multicenter, prospective, cohort study (UMIN clinical trial registry number: UMIN000020038). The design and cohort thereof have been reported previously [3]. Recruited patients were screened based on eGFR, were enrolled after checking according to the eligibility and exclusion criteria, and underwent physical examination and laboratory tests (e.g., hematology, blood biochemistry, anthropometric measurements, and urinalysis).

Study population

The CKD-JAC Study was conducted between April 2007 and March 2013 in Japanese patients with CKD who were under nephrology care. The study recruited 3087 patients at 17 medical institutions, from whom 121 were withdrawn, excluded, or lost to follow-up. The key eligibility criteria were Japanese, age 20–75 years, eGFR: 10–59 mL/min/1.73 m², no initiation of renal replacement therapy (RRT), and provision of written informed consent. The key exclusion criteria were polycystic kidney disease (PKD), human immunodeficiency virus infection, cirrhosis, cancer bearing, cancer treatment in the past 2 years, and renal transplantation. Furthermore, patients were excluded from statistical analyses when retracting previous consent completely or having no information at 6 months after the study onset. All patients gave written informed consent before enrollment in the study.

Primary endpoint

The primary endpoint was defined as a composite of two renal events: time to a 50 % decline in eGFR from baseline or time to the initiation of RRT. The following formulae for Japanese individuals were used to calculate eGFR by gender [8]: for males, eGFR (mL/min/1.73 m²) = 194 × [age]⁻0.287 × [serum creatinine (mg/dL)]⁻1.094; and for females, eGFR (mL/min/1.73 m²) = 194 × [age]⁻0.287 × [serum creatinine (mg/dL)]⁻1.094 × 0.739. A 50 % decline in eGFR from baseline was detected at the first of three consecutive visits when the renal event occurred. Furthermore, the correlations of serum creatinine (Cre) concentrations measured at respective institutions and the central laboratories were examined, and the former concentrations corrected with the latter ones were used to address the interinstitutional heterogeneity of the data obtained. Furthermore, the functional relationship analysis estimating errors in the values measured at respective institutions and the central laboratories was conducted to make necessary corrections. The central laboratories measured serum Cre, urinary excretion of albumin (Alb), parathyroid hormone, and fibroblast growth factor (FGF) 23 concentration.

Secondary endpoints

The following four renal events were established as the secondary endpoints: (1) rate of decline in eGFR from baseline. The slope of the regression line was calculated based on all eGFRs that had been determined between the onset of the study and the final determination point of eGFR and on the number of days from the onset of the study; (2) time to a 50 % decline in eGFR from baseline; (3) time to the initiation of RRT; and (4) time to doubling of serum Cre concentration. The number of days before the first of three consecutive visits after the onset of the study, at which serum Cre concentration doubled against the baseline value, was determined.
Candidate risk factors for CKD progression to ESRD

Among traditional and nontraditional risk factors, we examined the following as candidate risk factors for CKD progression to ESRD that were assessed with the renal event-based primary and secondary endpoints: age, gender, complication of DM, history of CVD, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), concurrent medications [erythropoiesis-stimulating agents (ESAs), ARBs and/or ACEIs], hemoglobin (Hb), Alb, C-reactive protein, blood urea nitrogen (BUN), Cre, eGFR, and urine albumin-to-creatinine ratio (UACR).

Associations of BPs with the primary endpoint

Blood pressure pattern 1

Patients were categorized to two BP groups (the ≥140 mmHg in SBP and/or ≥90 mmHg in DBP group; and the <140 mmHg in SBP and <90 mmHg in DBP group), and these two groups were then compared with respect to the primary endpoint.

Blood pressure pattern 2

Patients were categorized to the following seven BP groups according to the Japanese Society for Hypertension’s criteria: optimal (<120 mmHg in SBP and <80 mmHg in DBP), normal (120–129 mmHg in SBP and/or 80–84 mmHg in DBP), high normal (130–139 mmHg in SBP and/or 85–89 mmHg in DBP), grade 1 hypertension (140–159 mmHg in SBP and/or 90–99 mmHg in DBP), grade 2 hypertension (160–179 mmHg in SBP and/or 100–109 mmHg in DBP), grade 3 hypertension (≥180 mmHg in SBP and/or ≥110 mmHg in DBP), and isolated systolic hypertension (<140 mmHg in SBP and <90 mmHg in DBP), and seven groups were then compared with respect to the primary endpoint.

Statistical analyses

The associations of risk factors with CKD progression to ESRD were analyzed according to the Cox and Poisson regression models, preceded by the confirmation of correlations among risk factors and of multicollinearity. Regression diagnosis using the lever and covariate ratios was made to assess the observed values with a great association. The log–log plots were prepared in Cox regression, while residual diagnosis was made in Poisson regression. The models considering interactions were applied to both Cox and Poisson regressions in an attempt to select risk factors according to the stepwise method. The multivariate Cox proportional hazards models were used to explore the risk factors for the primary and secondary endpoints mentioned above. We did not establish the threshold for correlation coefficient but verified that all variables used had a correlation coefficient of less than 0.6, thus showing no severe multicollinearity (variance inflation factor: <10). Multivariate analyses were made using the data from 1331 patients about whom all variables had been measured in the complete case analysis, and we used the multiple imputation method to handle the missing data.

The Kaplan–Meier curves were prepared to estimate the cumulative incidence of the primary endpoint, and the log-rank test was conducted to compare two and seven groups with respect to BP patterns 1 and 2, respectively. A two-tailed value of $P < 0.05$ was considered statistically significant. All statistical analyses were made using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results

Baseline characteristics of patients

A total of 2966 patients were enrolled (Fig. 1), and patient characteristics at baseline by CKD stage are shown in Table 1. Females accounted for 37.9 %, and the age of the patients was 60.3 ± 11.6 years (mean ± SD); 43.8 % of the patients were elderly (65–77 years of age). Furthermore, 37.7 and 31.6 % of the patients had DM and increased UACR ≥1000 mg/g Cre, respectively. The mean eGFR was 28.9 ± 12.2 mL/min/1.72 m². The median duration of follow-up was approximately 3.9 years. In concert with CKD stage at baseline, the higher values ($P < 0.0001$) were obtained with respect to age, history of CVD, SBP, pulse pressure, BUN, uric acid (UA), UACR ≥1000 mg/g Cre, UACR ≥1000 mg/g Cre, ESAs, and sodium bicarbonate, as well as serum Cre, phosphorus, parathyroid hormone, and log FGF23; the lower values ($P < 0.0001$) were obtained with respect to BMI, eGFR, and Hb, as well as serum Alb, calcium (Ca), and lipids.

Time-course changes in the primary endpoint by CKD stage at baseline

The Kaplan–Meier curves for primary endpoint renal event-free Japanese patients with CKD according to CKD stage at baseline are shown in Fig. 2. The incidence of the primary endpoint increased significantly ($P < 0.0001$) in concert with CKD stage at baseline.
Associations of risk factors with the primary endpoint

Multivariate analysis disclosed that the following risk factors were significantly associated with the primary endpoint: current smoker, sodium bicarbonate, increases in BMI, SBP, UACR 300–999 mg/g Cre, UACR ≥1000 mg/g Cre, and serum Cre; and decreases in eGFR, serum Alb, and Hb. Among these variables, multivariate analysis revealed that only the following two variables showed a \( P \) value of <0.0001: elevated SBP at baseline [hazard ratio (HR) 1.203; 95 % confidence interval (CI) 1.099–1.318] and increased UACR at baseline (HR 4.523; 95 % CI 3.098–6.604) (Table 2).

Associations of risk factors with the secondary endpoints

1. Rates of decline in eGFR.
   The rates of decline in eGFR per year exhibited a significant tendency to be higher for greater CKD stage and higher UACR (trend \( P = 0.003 \) and <0.0001, respectively; Table 3). Especially, the mean of the rates in patients who had increased UACR decreased significantly (\( P < 0.0001 \)) by eightfold faster than those who had a UACR of <300 mg/g Cre. Furthermore, multiple Cox regression analysis revealed that the following risk factors were significantly associated with the rate of decline in eGFR: younger age and male gender; increases in SBP, UACR 300–999 mg/g Cre, and UACR ≥1000 mg/g Cre, UA, BUN, and serum phosphorus; and decreases in BMI and serum Ca (Supplement 1).

2. Time to a 50 % decline in eGFR from baseline.
   Multiple Cox regression analysis revealed that the following risk factors were significantly associated with time to a 50 % decline in eGFR from baseline: male gender, and administration of ESAs; increases in BMI, SBP, serum phosphorus, 300–999 mg/g Cre, and ≥1000 mg/g Cre; and decreases in eGFR, UA, serum Alb, and Hb (Supplement 2).

3. Time to the initiation of RRT.
   Multiple Cox regression analysis revealed that the following risk factors were significantly associated with time to the initiation of RRT: younger age, male gender, history of CVD, and administration of sodium bicarbonate; increases in SBP, UACR 300–999 mg/g Cre, UACR ≥1000 mg/g Cre, serum Cre, and log FGF23; and decreases in eGFR, serum Alb, and Hb (Supplement 3).

4. Time to doubling of serum Cre concentration.
   Multiple Cox regression analysis revealed that the following risk factors were significantly associated with time to doubling of serum Cre concentration: younger age, male gender, and administration of ESAs; increases in BMI, SBP, UACR 300–999 mg/g Cre, and UACR ≥1000 mg/g Cre; and decreases in eGFR, UA, serum Alb, and Hb (Supplement 4).

Incidence rates by CKD stage of the primary and secondary endpoints

The incidence rates (1000 person-years of follow-up) of both the primary and secondary endpoints increased in nearly full association with CKD stage at baseline (Table 4).

Primary endpoint according to two BP patterns at baseline

The incidences of the primary endpoint were compared between the following two BP pattern groups according to BP pattern 1: the ≥140 mmHg in SBP and/or ≥90 mmHg in DBP group; and the <140 mmHg in SBP and <90 mmHg in DBP group. The Kaplan–Meier curves for primary endpoint renal event-free Japanese patients with CKD according to BP pattern 1 are shown (Fig. 3a).
| Characteristics                                      | (n)          | Stage G3a, (Stage G3b, n (Stage G4), n (Stage G5, n (466) | Trend P |
|------------------------------------------------------|--------------|-------------------------------------------------------------|---------|
| Age, years                                           | 60.3 ± 11.6  | 54.7 ± 13.4, 59.9 ± 12.0, 61.5 ± 10.6, 62.1 ± 10.6       | <0.0001 |
| Female, %                                            | 37.9 (2966)  | 36.9, 35.4, 38.6, 42.7                                     | 0.018   |
| Diabetes mellitus, %                                 | 37.7 (2966)  | 31.4, 36.3, 38.8, 42.1                                     | 0.001   |
| History of cardiovascular disease, %                 | 23.0 (2966)  | 16.7, 21.3, 24.0, 28.5                                     | <0.0001 |
| Body mass index, kg/m²                                | 23.5 ± 3.8 (2678) | 24.3 ± 3.6, 23.7 ± 3.9, 23.3 ± 3.8, 23.2 ± 3.7         | <0.0001 |
| Systolic blood pressure, mmHg                       | 131.7 ± 18.6 (2923) | 129.0 ± 17.3, 130.1 ± 17.9, 132.1 ± 19.1, 136.2 ± 19.0 | <0.0001 |
| Diastolic blood pressure, mmHg                       | 76.3 ± 11.8 (2920) | 76.3 ± 11.3, 76.5 ± 11.4, 76.0 ± 12.2, 76.4 ± 12.2 | 0.966   |
| Pulse pressure, mmHg                                 | 55.4 ± 14.3 (2921) | 52.7 ± 13.1, 53.6 ± 13.8, 56.1 ± 14.5, 59.7 ± 14.3 | <0.0001 |
| Current smoker, %                                     | 44.9 (2521)  | 43.7, 46.2, 45.2, 41.9                                     | 0.454   |
| eGFR, mL/min/1.73 m²                                  | 28.9 ± 12.2 (2966) | 50.5 ± 4.9, 37.1 ± 4.2, 22.5 ± 4.3, 11.8 ± 2.0         | <0.0001 |
| Serum creatinine, mg/dL                              | 2.15 ± 1.06 (2966) | 1.11 ± 0.17, 1.44 ± 0.25, 2.29 ± 0.52, 4.05 ± 0.90 | <0.0001 |
| Blood urea nitrogen, mg/dL                           | 31.5 ± 14.7 (2925) | 19.0 ± 5.0, 23.5 ± 6.6, 34.1 ± 11.5, 50.9 ± 17.0 | <0.0001 |
| Hemoglobin, g/dL                                     | 12.1 ± 1.8 (2920) | 13.3 ± 1.8, 12.8 ± 1.8, 11.7 ± 1.6, 10.6 ± 1.3         | <0.0001 |
| Uric acid, mg/dL                                     | 7.18 ± 1.56 (2901) | 6.59 ± 1.48, 7.03 ± 1.39, 7.35 ± 1.60, 7.49 ± 1.73 | <0.0001 |
| Serum albumin, g/dL                                  | 3.97 ± 0.43 (2870) | 4.09 ± 0.41, 4.01 ± 0.42, 3.93 ± 0.42, 3.89 ± 0.45 | <0.0001 |
| Serum calcium, mg/dL                                 | 9.01 ± 0.53 (2718) | 9.21 ± 0.43, 9.11 ± 0.46, 8.99 ± 0.49, 8.70 ± 0.65 | <0.0001 |
| Serum phosphorus, mg/dL                              | 3.53 ± 0.69 (2624) | 3.27 ± 0.57, 3.31 ± 0.59, 3.55 ± 0.62, 4.11 ± 0.77 | <0.0001 |
| Serum parathyroid hormone, pg/mL                     | 106.3 ± 92.6 (2755) | 56.0 ± 26.4, 68.1 ± 34.9, 109.2 ± 70.9, 216.2 ± 147.2 | <0.0001 |
| Total cholesterol, mg/dL                             | 194.2 ± 43.3 (2479) | 201.6 ± 43.8, 197.0 ± 43.8, 192.1 ± 41.1, 187.5 ± 45.8 | <0.0001 |
| High-density cholesterol, mg/dL                      | 54.5 ± 18.4 (2126) | 57.2 ± 18.5, 56.0 ± 18.6, 53.5 ± 18.3, 51.5 ± 17.5 | <0.0001 |
| Low-density cholesterol, mg/dL                       | 108.2 ± 33.0 (2231) | 114.0 ± 28.6, 110.1 ± 34.5, 106.4 ± 31.0, 103.8 ± 36.2 | <0.0001 |
| Triglycerides, mg/dL                                 | 167.0 ± 109.3 (2512) | 175.2 ± 133.2, 165.9 ± 108.4, 168.6 ± 110.4, 159.5 ± 87.2 | 0.097   |
| Ferritin, ng/mL                                       | 137.2 ± 136.6 (1539) | 130.4 ± 124.6, 124.8 ± 120.5, 142.6 ± 153.0, 153.0 ± 131.5 | 0.041   |
| C-reactive protein, mg/dL                            | 0.10 (0.04–0.20) (40.04–0.15) | 0.08 (0.04–0.15), 0.10 (0.04–0.20), 0.10 (0.04–0.20), 0.08 (0.03–0.20) | 0.064† NC |
| Fibroblast growth factor 23, pg/mL                   | 56.70 (40.10–91.30) | 39.20 (30.70–51.30), 46.60 (35.90–64.10), 62.45 (46.80–94.00), 109.60 (71.30–176.80) | 0.0001   |
| Log fibroblast growth factor 23a                     | 4.24 ± 0.91 (2709) | 3.85 ± 0.83, 4.01 ± 0.80, 4.30 ± 0.89, 4.85 ± 0.93                 | <0.0001   |
| UACR 300–999 mg/g Cre, %                             | 28.2 (2713)  | 21.1, 27.1, 30.4, 30.0                                     | <0.0001   |
| UACR ≥1000 mg/g Cre, %                               | 31.6 (2713)  | 15.4, 21.9, 36.1, 52.0                                     | <0.0001   |
| ARBs or ACEIs, %                                      | 81.8 (2966)  | 76.5, 80.7, 84.3, 82.0                                     | 0.013   |
| Erythropoiesis-stimulating agents, %                 | 13.2 (2966)  | 1.0, 2.9, 15.5, 38.6                                     | <0.0001   |
The incidence of the primary endpoint increased significantly ($P < 0.0001$) in the $\geq 140$ mmHg in SBP and/or $\geq 90$ mmHg in DBP group. The incidences of the primary endpoint were compared among the following seven BP category groups according to BP pattern 2: the optimal group; the normal group; the high normal group; the grade 1 hypertension group; the grade 2 hypertension group; the grade 3 hypertension group; and the isolated systolic hypertension group. The Kaplan–Meier curves for primary endpoint renal event-free Japanese patients with CKD according to BP pattern 2 in seven groups are shown (Fig. 3b). A significant difference ($P < 0.0001$) was found among the seven groups with respect to the primary endpoint.

**Primary endpoint according to UACR at baseline**

The incidences of the primary endpoint were calculated in three UACR ($<300$, $300–999$, and $\geq 1000$ mg/g Cre) categories. The Kaplan–Meier curves for Japanese patients
with CKD according to these three categories of UACR at baseline are shown in Fig. 4. The incidence of the primary endpoint increased significantly (P < 0.0001) among the three UACR groups.

Discussion

The present study is the first, large-scale, multicenter, prospective cohort study in Japanese patients with CKD under nephrology care, which aimed at identifying risk factors for CKD progression to ESRD. Our study disclosed the following facts: (1) elevated SBP and increased UACR, both at baseline, were significantly associated (HR 1.203, 95 % CI 1.099–1.318 and HR 4523, 95 % CI 3.098–6.604; P < 0.0001, respectively) with the primary endpoint; and (2) the deterioration of a powerful predictor of ESRD, proteinuria (which was translated into higher UACR), accelerated CKD progression to ESRD extensively. These findings are in concert with previous clinical studies indicating that lower eGFR and higher UACR are independently associated with the increased risks of CVD and ESRD.

Numerous previous studies have indicated that hyper-tension is one of the important risk factors for renal impairment. In the present study, SBP at baseline was significantly associated with both the primary and secondary endpoints. On the other hand, DBP was not associated with a decline in renal function. Furthermore, the primary endpoint was analyzed according to two patterns of BPs. Consequently, the number of patients who developed a primary endpoint renal event increased in parallel with the severity of hypertension at baseline—a finding that is concordant with a previous study [9]. Statistical

Table 2 Associations of variables with a composite of time to a 50 % decline in estimated glomerular filtration rate from baseline or time to the initiation of renal replacement therapy of Japanese patients with chronic kidney disease according to the multiple Cox regression analysis

| Variables                                                                 | Univariate                                                                 | Multivariate (n = 1331)        |
|---------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------|
|                                                                           | HR (95 % CI)                  | P value | HR (95 % CI)                  | P value |
| Age, per 1 year greater                                                   | 1.001 (0.994–1.008)           | 0.767   | 0.988 (0.975–1.001)           | 0.068   |
| Male gender                                                               | 1.600 (1.344–1.904)           | <0.0001 | 1.272 (0.884–1.831)           | 0.195   |
| Diabetes mellitus                                                         | 1.663 (1.418–1.949)           | <0.0001 | 0.907 (0.694–1.185)           | 0.474   |
| History of cardiovascular disease                                         | 1.295 (1.080–1.552)           | 0.005   | 0.823 (0.628–1.078)           | 0.158   |
| Body mass index, per kg/m² greater                                        | 1.029 (1.007–1.051)           | 0.011   | 1.050 (1.014–1.087)           | 0.006   |
| Systolic blood pressure, per 10 mmHg greater                             | 1.213 (1.165–1.264)           | <0.0001 | 1.203 (1.099–1.318)           | <0.0001 |
| Diastolic blood pressure, per 10 mmHg greater                             | 1.290 (0.700–2.379)           | 0.415   | 0.852 (0.368–1.975)           | 0.709   |
| Current smoker[7]                                                         | 1.730 (1.413–2.118)           | <0.0001 | 1.542 (1.126–2.113)           | 0.007   |
| Ex-smoker[8]                                                              | 1.232 (1.023–1.483)           | 0.028   | 1.253 (0.931–1.686)           | 0.138   |
| Estimated glomerular filtration rate                                      | 0.903 (0.895–0.912)           | <0.0001 | 0.969 (0.944–0.995)           | 0.021   |
| Uric acid                                                                 | 1.134 (1.078–1.192)           | <0.0001 | 0.948 (0.882–1.019)           | 0.144   |
| Serum albumin                                                             | 0.317 (0.268–0.374)           | <0.0001 | 0.731 (0.540–0.989)           | 0.042   |
| Serum creatinine                                                          | 2.455 (2.313–2.605)           | <0.0001 | 1.589 (1.228–2.056)           | <0.001  |
| Blood urea nitrogen                                                       | 1.044 (1.041–1.048)           | <0.0001 | 0.997 (0.985–1.008)           | 0.585   |
| Hemoglobin                                                                | 0.707 (0.675–0.740)           | <0.0001 | 0.858 (0.781–0.941)           | 0.001   |
| Total cholesterol                                                         | 0.999 (0.997–1.001)           | 0.325   | 1.000 (0.998–1.003)           | 0.734   |
| High-sensitivity C-reactive protein                                       | 1.077 (0.977–1.187)           | 0.135   | 1.037 (0.941–1.142)           | 0.466   |
| Serum phosphorus                                                          | 1.945 (1.783–2.121)           | <0.0001 | 1.207 (0.982–1.484)           | 0.074   |
| Serum calcium                                                             | 0.302 (0.266–0.343)           | <0.0001 | 0.792 (0.604–1.038)           | 0.091   |
| Log fibroblast growth factor 23                                           | 1.416 (1.324–1.514)           | <0.0001 | 0.992 (0.853–1.153)           | 0.916   |
| UACR, 300–999 mg/g Cre                                                    | 3.805 (2.866–5.051)           | <0.0001 | 2.127 (1.432–3.160)           | <0.001  |
| UACR, >1000 mg/g Cre                                                      | 10.444 (8.049–13.552)         | <0.0001 | 4.523 (3.098–6.604)           | <0.0001 |
| ARBs and/or ACEIs                                                         | 1.361 (1.082–1.711)           | 0.008   | 0.848 (0.608–1.183)           | 0.332   |
| Erythropoiesis-stimulating agents                                         | 2.931 (2.437–3.526)           | <0.0001 | 0.908 (0.671–1.227)           | 0.529   |
| Statins                                                                   | 1.050 (0.894–1.232)           | 0.552   | 0.931 (0.732–1.185)           | 0.563   |
| Sodium bicarbonate                                                       | 2.590 (2.114–3.174)           | <0.0001 | 1.340 (1.004–1.788)           | 0.047   |

* Against the reference “nonsmoker”

HR hazard ratio, CI confidence interval, UACR urine albumin-to-creatinine ratio, ARBs angiotensin receptor blockers, Cre creatinine, ACEIs angiotensin-converting enzyme inhibitors
Stage G3a, eGFR: 45–59 mL/min/1.73 m²; stage G3b, eGFR: 30–44 mL/min/1.73 m²; stage G4, eGFR: 15–29 mL/min/1.73 m²; stage G5, eGFR:< 15 mL/min/1.73 m².

Values are expressed as mean ± SD

**Table 3** Rates of decline in eGFR per year

| eGFR                  | Mean ± SD | P value | Trend P |
|-----------------------|-----------|---------|---------|
| Stage G3a             | −1.925 ± 5.681 | 0.003   | 0.003   |
| Stage G3b             | −2.056 ± 5.924 |         |         |
| Stage G4              | −3.182 ± 14.189 |         |         |
| Stage G5              | −3.754 ± 6.374 |         |         |
| Hypertension          |           |         |         |
| Group 1               | −3.480 ± 6.650 | 0.154   |         |
| Group 2               | −2.641 ± 10.440 |         |         |
| UACR (mg/g Cre)       |           |         |         |
| <300                  | −0.546 ± 4.690 | <0.0001 | <0.0001 |
| 300–999              | −2.399 ± 6.297 |         |         |
| ≥1000                 | −4.560 ± 4.894 |         |         |

Values are expressed as mean ± SD

Stage G3a, eGFR: 45–59 mL/min/1.73 m²; stage G3b, eGFR: 30–44 mL/min/1.73 m²; stage G4, eGFR: 15–29 mL/min/1.73 m²; stage G5, eGFR: <15 mL/min/1.73 m².

Table 4 Incidence rates of the primary and secondary endpoints

| CKD stages | Primary endpointa | Secondary endpoints |
|------------|-------------------|---------------------|
|            | Rate of decline in eGFR from baseline | Time to a 50 % decline in eGFR from baseline | Time to the initiation of RRT | Time to doubling of serum Cre concentration |
| G3a        | 18.3              | 17.4                | 4.5                   | 16.4                     |
| G3b        | 28.1              | 27.0                | 13.1                 | 22.8                     |
| G4         | 96.4              | 82.0                | 63.1                 | 68.9                     |
| G5         | 439.4             | 101.1               | 265.7                | 68.2                     |

Values are expressed as number of renal events (rate per 1000 person-years of follow-up)

a A composite of time to a 50 % decline in eGFR from baseline or time to the initiation of RRT

Stage G3a, eGFR: 45–59 mL/min/1.73 m²; stage G3b, eGFR: 30–44 mL/min/1.73 m²; stage G4, eGFR: 15–29 mL/min/1.73 m²; stage G5, eGFR: <15 mL/min/1.73 m²

CKD chronic kidney disease, eGFR estimated glomerular filtration rate, RRT renal replacement therapy, Cre creatinine, NC not calculable
renal endpoints when using hypertensive nephropathy as reference. However, we did not find any strong association between concurrent DM and the primary endpoint in the present study. Not all of patients, who had DM as underlying disease, developed diabetic nephropathy; the proportion of the relevant patients was no more than 55 %, a figure that had been described in our prior study [2]. The present study seems to have included a number of diabetic patients whose underlying disease was nephrosclerosis, which probably led to failure in extracting DM as a risk factor. We speculate that this unexpected finding is presumably attributable to the fact that many patients with DM have hypertensive nephropathy concurrently.

Voormolen et al. [14] reported a significant association (HR 0.178) between serum phosphorus level and the rate of decline in eGFR from baseline in patients with stage 4/5 CKD and conjectured that the association was attributable to the progression of arteriosclerosis caused by protein and phosphorus loads. In the present study, however, we did not find any significant association of elevated serum phosphorus level with the primary or secondary endpoints. Furthermore, we detected significant
associations (HRs 1.050–1.090) between elevated BMI and the primary endpoint and some secondary endpoints. Of significance was the fact that elevated BMI was extracted as a risk factor similar to a previous study in Japan [15] even in a cohort of patients with CKD whose mean BMI was as low as 23.5 kg/m². Also, we consider that the present study is clinically relevant in that the primary and secondary endpoints were examined in patients with CKD who were under nephrology care; not less than 80 % of them received ARBs and/or ACEIs, and their BPs (132 ± 19 mmHg in SBP/76 ± 12 mmHg in DBP) were under control to the levels at which the target BPs were almost reached. Our study is distinguishably featured by the precise assessment of renal events, including the rate of decline in eGFR from baseline, through the more meticulous care (e.g., frequent blood collections) of patients as compared with previous studies in Westerners.

Our study has several limitations. First, patient characteristics were determined only at baseline and once. Second, the GFR to assess the renal function of patients was not precisely calculated based on inulin clearance but was estimated with the serum creatinine-based equation. Third, selection bias cannot be ruled out, because patients were mostly enrolled at large-sized hospitals that can provide nephrology care.

In conclusion, elevated SBP and increased UACR were the risk factors significantly associated with CKD progression to ESRD in Japanese patients with CKD. Therefore, clinicians should constantly give heed, in the routine clinical setting, especially to advanced CKD patients with poorly controlled hypertension and increased UACR in an attempt to curb CKD progression to ESRD.

Acknowledgments The authors thank Satoshi Sakima, MD, for his gracious review of the manuscript. This study was supported by research funds with no restriction on publication from Kyowa Hakko Kirin Co., Ltd.

This study was conducted by principal investigators at the following medical centers: Japan Community Health care Organization Sendai Hospital (Miyagi), JA Toride Medical Center (Ibaraki), Jichi Medical University (Tochigi), Tokyo Women’s Medical University Hospital (Tokyo), St. Luke’s International Hospital (Tokyo), Showa University Hospital (Tokyo), Showa University Yokohama Northern Hospital (Kanagawa), Showa University Fujigaoka Hospital (Kanagawa), Gifu Prefectural General Medical Center (Gifu), Kasugai Municipal Hospital (Aichi), Tosei General Hospital (Aichi), Osaka University Hospital (Osaka), Osaka General Medical Center (Osaka), Osaka City General Hospital (Osaka), Kurashiki Central Hospital (Okayama), Fukuoka Red Cross Hospital (Fukuoka), Iizuka Hospital (Fukuoka).

List of Institutional Review Boards at participating institutions:
1. Japan Community Health Care Organization Sendai Hospital (April 4, 2007)
2. JA Toride Medical Center (No. 61)
3. Jichi Medical University (07-18)
4. Tokyo Women’s Medical University Hospital (1106)
5. St. Luke’s International Hospital (10-034)
6. Showa University Hospital (507)
7. Showa University Yokohama Northern Hospital (0705-02)
8. Showa University Fujigaoka Hospital (2007578)
9. Gifu Prefectural General Medical Center (August 1, 2007)
10. Kasugai Municipal Hospital (44)
11. Tosei General Hospital (92)
12. Osaka University Hospital (07083)
13. Osaka General Medical Center (June 12, 2007)
14. Osaka City General Hospital (137-20)
15. Kurashiki Central Hospital (19-14)
16. Fukuoka Red Cross Hospital (58)
17. Iizuka Hospital (March 14, 2007)

Compliance with ethical standards
Conflict of interest TW has received a research support Grant from Kyowa Hakko Kirin. KN has consulted for and received a research support Grant from Kyowa Hakko Kirin. TA has consulted for and received lecture free from Kyowa Hakko Kirin. HM has received speaker honoraria and a support Grant from Kyowa Hakko Kirin. Other authors have nothing to declare.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.
2. Imai E, Matsu S, Makino H, et al. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol. 2010;14:558–70.
3. Imai E, Matsu S, Makino H, et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008;31:1101–7.
4. Lash JP, Go AS, Appel LJ, et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol. 2009;4:1302–11.
5. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the US. J Am Soc Nephrol. 2003;14:2902–7.
6. Barbour SJ, Er L, Durdjev O, et al. Differences in progression of CKD and mortality amongst Caucasian, Oriental Asian and South Asian CKD patients. Nephrol Dial Transplant. 2010;25:3663–72.
7. Kidney Disease: Improving Global Outcomes (KDIGO): CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013:3:1–150.
8. Matsu S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
9. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41:1341–5.
10. Jafar TH, Stark PC, Schmid CH, et al. Angiotensin-converting enzyme inhibition and progression of renal disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–40.
11. Iseki K, Ikemiya Y, Iseki C, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.
12. Yang W, Xie D, Anderson AH, et al. Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2014;63:236–43.
13. De Nicola L, Provenzano M, Chiodini P, et al. Independent role of underlying kidney disease on renal prognosis of patients with chronic kidney disease under nephrology care. PLoS One. 2015;10:e0127071.
14. Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007;22:2909–16.
15. Iseki K. Body mass index and the risk of chronic renal failure: the Asian experience. Contrib Nephrol. 2006;151:42–56.